Article

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccination

2021-01-11

Abstract excerpt

The severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2) has emerged as the infectious agent causing the pandemic coronavirus disease 2019 (COVID-19) with dramatic consequences for global human health and economics. Previously, we reached clinical evaluation with our vector vaccine based on vaccinia virus MVA against the Middle East respiratory syndrome coronavirus (MERS-CoV), which causes an infect...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 34aabbcb-2055-5db8-97d3-e77da0660f0d
DOI: 10.1101/2021.01.09.426032

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccinationDOI 10.1101/2021.01.09.426032Read

Immunogenicity and efficacy of Ad26. COV2 .S: An adenoviral vector–based COVID ‐19 vaccineSemantic proximity Read

Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamstersSemantic proximity Read

Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responsesSemantic proximity Read

Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19Semantic proximity Read

Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trialSemantic proximity Read

An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaquesSemantic proximity Read

MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humansSemantic proximity Read

DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in miceSemantic proximity Read

COVID-19 Vaccines: Where Do We Stand at the End of 2023?Semantic proximity Read

A Newcastle disease virus-vector expressing a prefusion-stabilized spike protein of SARS-CoV-2 induces protective immune responses against prototype virus and variants of concern in mice and hamstersSemantic proximity Read

Translational Virology - COVID-19, The Perfect ExampleSemantic proximity Read

SARS-CoV-2 vaccines - the biggest medical research project of the 21st century.Semantic proximity Read